BETA: Please send your feedback!
Reata Pharmaceuticals
RETA:NAS
Pharmaceuticals: Major
$4.46bn
SMALL cap
$182.26
(-2.65%)
2.30%
since start of 2019
-44.94
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Pharmaceuticals: Major
Founded 2002
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its products include cardiovascular, rare diseases, immune-oncology, and ophthalmology. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
website
Headquarters
Executives
| Name | Title | Gender |
| W. Christian Wigley, PhD | Vice President-Research & Founding Scientist | Male |
| Michael D. Wortley | Chief Legal Officer & Vice President | Male |
| J. Warren Huff | Chairman, Chief Executive Officer & President | Male |
| Jason Wilson, MBA, CPA | Chief Financial Officer & Vice President-Strategy | Male |
| Jef Karel de Brabander | Founder | Male |
| Waldemar Priebe, PhD | Founder | Male |
| Philip J. Thomas | Founder | Male |
| Colin Meyer, MD, MBA | Chief Medical Officer & VP-Product Development | Male |
| Thomas C. Sdhof, MD | Founder | Male |
| Joel Proksch, PhD | Vice President-Regulatory & Development | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Reata Pharmaceuticals - Competitors and Related Companies
How Reata Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Major industry or with competing business segments.
Reata Pharmaceuticals
RETA:NAS
Pharmaceuticals: Major
$4.46bn
SMALL cap
$182.26
(-2.65%)
2.30%
since start of 2019
-44.94
Loading…